Consistent with our previous review , several domains of GA are associated with adverse outcomes .
BACKGROUND Our previous systematic review of geriatric assessment ( GA ) in oncology included a literature search up to November 2010 .
However , the quickly evolving field warranted an up date .
Aims of this review : ( i ) provide an overview of all GA instruments developed and /or in use in the oncology setting ; ( ii ) evaluate effectiveness of GA in predicting/modifying outcomes ( e.g. treatment decision impact , treatment toxicity , mortality , use of care ) .
Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study.
Few data are available to help predict which older cancer patient is at risk of developing chemotherapy-related toxicity . This study was a pilot for a project design ing a predictive risk score . Chemotherapy patients aged 70 years and older were prospect ively enrolled .  Chemotherapies were adjusted for their published toxicity . 60 patients were enrolled , 59 were evaluable . Mean dose-intensity was 90.3 % , range 33.3 - 129.0 % . 47 % of the patients experienced grade 4 haematological and /or grade 3 - 4 non-haematological toxicity . Published toxicity ( MAX2 ) , diastolic blood pressure , marrow invasion and lactate dehydrogenase ( LDH ) were all associated with toxicity ( P<0.1 ) ; Body Mass Index , previous chemotherapy , red blood cells , platelets , polymedication with dose-intensity ; and polymedication with FACT-G change . After adjustment for the published toxicity , the variables retained their significance , except for LDH and polymedication ( for dose-intensity ) . Although the size of this pilot study imposes a cautious interpretation , patient-related and chemotherapy-related variables correlated independently with toxicity . Design ing a composite predictive score to use in assessing the toxicity of multiple chemotherapy regimens therefore appears to be a valid undertaking
Consistent with our previous review , several domains of GA are associated with adverse outcomes .
BACKGROUND Our previous systematic review of geriatric assessment ( GA ) in oncology included a literature search up to November 2010 .
However , the quickly evolving field warranted an up date .
Aims of this review : ( i ) provide an overview of all GA instruments developed and /or in use in the oncology setting ; ( ii ) evaluate effectiveness of GA in predicting/modifying outcomes ( e.g. treatment decision impact , treatment toxicity , mortality , use of care ) .